Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.33 |
| ▸ | CA12 | O43570 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | BTN3A1 | O00481 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1741146 | 1.00 | SMN1; SMN2 (0.35) | SMN1; SMN2CA14CA12ALDH1A1CA1 | |
| SCHEMBL1741149 | 1.00 | SMN1; SMN2 (0.35) | SMN1; SMN2CA14CA12ALDH1A1CA1 | |
| SCHEMBL28766688 | 0.83 | KMT2A (0.34) | CA14CA12CA1CA2 | |
| SCHEMBL9558025 | 0.83 | — | — | |
| SCHEMBL12769953 | 0.80 | SMN1; SMN2 (0.33) | SMN1; SMN2CA14CA12ALDH1A1 | |
| SCHEMBL1828667 | 0.80 | MMP8 (0.35) | ALDH1A1 | |
| SCHEMBL12769955 | 0.80 | SMN1; SMN2 (0.33) | SMN1; SMN2CA14CA12ALDH1A1 | |
| SCHEMBL31054671 | 0.80 | MMP8 (0.35) | ALDH1A1 | |
| SCHEMBL1578905 | 0.80 | MMP8 (0.35) | ALDH1A1 | |
| SCHEMBL1578908 | 0.80 | MMP8 (0.35) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114945571-B | Cyclic compounds and methods of use thereof | 薛定谔公司 | 2025-02-25 | — | — | CN | disclosed |
| EP-4499648-A1 | PROCESS FOR PREPARING SHP2 INHIBITORS | GENZYME CORPORATION (US) | 2025-02-05 | — | — | EP | disclosed |
| US-20240018157-A1 | CYCLIC COMPOUNDS AND METHODS OF USING SAME | SCHRÖDINGER, INC. | 2024-01-18 | — | — | US | disclosed |
| US-20240018157-A1 | CYCLIC COMPOUNDS AND METHODS OF USING SAME | SCHRÖDINGER, INC. | 2024-01-18 | — | — | US | disclosed |
| US-11827644-B2 | Pyrazine derivative and application thereof in inhibiting SHP2 | SUZHOU GENHOUSE PHARMACEUTICAL CO., LTD (CN) | 2023-11-28 | — | — | US | disclosed |
| WO-2023192112-A1 | PROCESS FOR PREPARING SHP2 INHIBITORS | GENZYME CORPORATION (US) | 2023-10-05 | — | — | WO | disclosed |
| US-20230227464-A1 | PYRAZINE DERIVATIVE AND APPLICATION THEREOF IN INHIBITING SHP2 | SUZHOU GENHOUSE PHARMACEUTICAL CO., LTD (CN) | 2023-07-20 | — | — | US | disclosed |
| US-20230219946-A1 | PYRIMIDIN-4(3H)-ONE HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL USE THEREOF | BEIJING INNOCARE PHARMA TECH CO., LTD. (CN) | 2023-07-13 | — | — | US | disclosed |
| US-20230219946-A1 | PYRIMIDIN-4(3H)-ONE HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL USE THEREOF | BEIJING INNOCARE PHARMA TECH CO., LTD. (CN) | 2023-07-13 | — | — | US | disclosed |
| EP-4092024-A1 | PYRIMIDINE-4(3H)-KETONE HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF IN MEDICINE AND PHARMACOLOGY | Beijing InnoCare Pharma Tech Co., Ltd. (CN) | 2022-11-23 | — | — | EP | disclosed |
| US-20150148313-A1 | MACROCYCLIC FACTOR VIIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2015-05-28 | — | — | US | disclosed |
| US-20150148313-A1 | MACROCYCLIC FACTOR VIIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2015-05-28 | — | — | US | disclosed |
| US-20150080391-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | GALAPAGOS NV (BE) | 2015-03-19 | — | — | US | disclosed |
| US-20150080391-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | GALAPAGOS NV (BE) | 2015-03-19 | — | — | US | disclosed |
| US-20150080391-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | GALAPAGOS NV (BE) | 2015-03-19 | — | — | US | disclosed |
| WO-2015024905-A1 | DERIVATIVES OF 1 H-PYRAZOLO[3,4-B]PYRIDINE AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | GALAPAGOS NV (BE) | 2015-02-26 | — | — | WO | disclosed |
| US-20120202287-A1 | Stem Cell Culture Methods | ITI SCOTLAND LIMITED (GB) | 2012-08-09 | — | — | US | disclosed |
| EP-2389436-A2 | STEM CELL CULTURE METHODS | ITI Scotland Limited (GB) | 2011-11-30 | — | — | EP | disclosed |
| US-20110257911-A1 | SYSTEMS AND METHODS FOR DETECTING CHANGES IN ENERGY USAGE IN A BUILDING | JOHNSON CONTROLS TECHNOLOGY COMPANY | 2011-10-20 | — | — | US | disclosed |
| WO-2010084300-A2 | STEM CELL CULTURE METHODS | ITI SCOTLAND LIMITED (GB) | 2010-07-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150148313-A1 | MACROCYCLIC FACTOR VIIA INHIBITORS | F7, F12, F5 | SMN1; SMN2 2825/4885CA14 2719/4885CA12 3451/4885 |
| US-11827644-B2 | Pyrazine derivative and application thereof in inhibiting SHP2 | PTPN5, PTPN1, PTPN7 | SMN1; SMN2 3529/4885CA14 3431/4885CA12 2586/4885 |
| US-20230227464-A1 | PYRAZINE DERIVATIVE AND APPLICATION THEREOF IN INHIBITING SHP2 | PTPN5, PTPN1, PTPN7 | SMN1; SMN2 3529/4885CA14 3431/4885CA12 2586/4885 |
| US-20120202287-A1 | Stem Cell Culture Methods | KIT, SOX18, MCL1 | SMN1; SMN2 1236/4885CA14 846/4885CA12 829/4885 |
| US-20150080391-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | FGF2, CCNA2, VEGFA | SMN1; SMN2 580/4885CA14 823/4885CA12 579/4885 |
| US-20230219946-A1 | PYRIMIDIN-4(3H)-ONE HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL USE THEREOF | PTPN5, PTPN1, JAK2 | SMN1; SMN2 2657/4885CA14 3614/4885CA12 3978/4885 |
| US-20240018157-A1 | CYCLIC COMPOUNDS AND METHODS OF USING SAME | MALT1, FKBP1B, FKBP1A | SMN1; SMN2 2382/4885CA14 369/4885CA12 391/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.